A case report from a 64-year-old Chinese woman diagnosed with NSCLC first showed that BCL11A was a novel ALK receptor tyrosine kinase (ALK) fusion gene [84], BCL11A–ALK showed certain resistance to ALK inhibitor crizotinib and considered as an oncogenic fusion gene. Here, BCL11A is linked to non-small cell lung carcinoma.